Yokneam, Israel-based Rapid Medical designed Tigertriever to remove thrombus from delicate brain blood vessels during an ischemic stroke. With National Medical Product Administration (NMPA) approval, it becomes the first device to offer patient-specific solutions for this treatment.
“This new approval for Tigertriever propels treatment for ischemic stroke patients in China,” said Ronen Eckhouse, co-founder and CEO at Rapid Medical. “We are fortunate to have an excellent partner with MicroPort Scientific Corporation, who understand the need to expand neurointerventional capabilities and individualized stroke care for these patients.”
Fueled by advancements in aerospace engineering, Tigertriever enables precise control during mechanical thrombectomy. Its unique operation changes the procedure from a passive to an active approach, accelerating clot capture. This also potentially reduces the risk of vascular injury during removal.
